香港20年人群研究:氯氮平相关中性粒细胞减少症的发生率
该研究基于香港电子健康记录,比较2003-2019年启动氯氮平或非氯氮平第二代抗精神病药(SGA)的精神分裂症患者,随访至2023年。发现氯氮平相关中性粒细胞减少风险在最初18周最高,约2年后与非氯氮平SGA持平,建议前18周每周监测、后每月监测至2年。
要点
- 氯氮平使用最初18周中性粒细胞减少风险显著高于非氯氮平SGA。
- 严重中性粒细胞减少调整后发生率两组相似(0.37 vs 0.36/100人年)。
- 风险在26-29周后急剧下降,82-135周(约2年)与非氯氮平SGA趋同。
核心结论
- 氯氮平相关中性粒细胞减少风险在治疗最初18周最高,约2年后降至与非氯氮平SGA相当水平。
研究设计与样本
- 回顾性队列研究,使用香港电子健康记录识别2003-2019年启动氯氮平或非氯氮平SGA的患者,随访至2023年。
主要发现
- 氯氮平组轻度中性粒细胞减少(ANC 1.0-1.5×10^9/L)未调整发生率为7.05% vs 3.74%,严重中性粒细胞减少(ANC<1.0×10^9/L)为2.53% vs 1.45%。
- 调整后严重中性粒细胞减少发生率两组相似(0.37 vs 0.36/100人年)。
- 最初18周内,氯氮平与轻度中性粒细胞减少风险升高相关(IRR 5.91;95%CI 3.96-8.70),严重中性粒细胞减少风险亦升高(IRR 3.48;95%CI 1.70-6.84)。
- 贝叶斯变点分析显示氯氮平相关风险在26-29周后急剧下降,82-135周(约2年)与非氯氮平SGA趋同;45岁以下患者未见显著早期超额风险,男性出现一过性轻度中性粒细胞减少风险。
关键数值与推荐
- 轻度中性粒细胞减少定义为ANC 1.0-1.5×10^9/L,严重中性粒细胞减少定义为ANC<1.0×10^9/L。
- 严重中性粒细胞减少导致6周内停用氯氮平视为氯氮平相关事件。
- 建议前18周每周监测血常规,之后每月监测至2年,可根据年龄和性别个体化调整监测计划。
临床怎么用
- 对氯氮平使用者,前18周应每周监测中性粒细胞计数,之后每月监测至2年。
- 45岁以下患者早期超额风险不显著,男性需关注一过性轻度中性粒细胞减少。
- 约2年后氯氮平相关中性粒细胞减少风险与非氯氮平SGA相当,可考虑调整监测频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is the gold standard for treatment-resistant schizophrenia, but its use is constrained by the risk of severe neutropenia, thus requiring mandatory lifelong hematological monitoring in many jurisdictions. However, a significant evidence gap persists regarding the long-term comparative risk profiles of clozapine versus other second-generation antipsychotics (SGAs), complicating shared decision-making. AIMS: To compare the risk of neutropenia associated with clozapine versus non-clozapine SGAs, assess temporal risk evolution and identify high-risk subgroups to optimise monitoring. METHOD: This retrospective cohort study used Hong Kong's electronic health records to identify patients initiating clozapine or non-clozapine SGAs (2003-2019), with follow-up until 2023. Outcomes included minor (absolute neutrophil count (ANC) 1.0-1.5 × 109/litre) and serious neutropenia (ANC <1.0 × 109/litre). Serious neutropenia leading to clozapine discontinuation within 6 weeks was considered clozapine-associated. RESULTS: Among 4868 clozapine and 38 277 non-clozapine SGA users, clozapine users showed higher unadjusted incidences of minor (7.05 v. 3.74%) and serious neutropenia (2.53 v. 1.45%). However, adjusted rates of serious neutropenia were similar between groups (0.37 v. 0.36 per 100 person-years). Clozapine was associated with higher risks of minor (incidence rate ratio (IRR) 5.91; 95% CI 3.96-8.70) and serious neutropenia (IRR 3.48; 1.70-6.84) in the first 18 weeks. Bayesian change-point analysis showed sharply declining clozapine-associated risk after 26-29 weeks, converging with non-clozapine SGAs by 82-135 weeks (around 2 years). No significant early excess risk was found in patients younger than 45, while males experienced a transient risk of minor neutropenia. CONCLUSIONS: The risk of clozapine-associated neutropenia is highest in the initial 18 weeks, declining to levels seen with non-clozapine SGAs by 2 years. Weekly monitoring for 18 weeks and monthly for up to 2 years is advisable, with potential for personalised schedules based on age and sex.
引用
- Zhou H, Luo H, Siskind D, et al. Incidence of clozapine-associated neutropenia in patients with schizophrenia: 20-year population-based study in Hong Kong. Br J Psychiatry. 2026. PMID: 42661560. doi:10.1192/bjp.2026.10726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。